"The aim of the study is to compare, in real life, the risk benefit (including both major
bleeding and thrombotic events (TE) and death from any cause) associated with direct oral
anticoagulants (DOAC) and with anti vitamin K (VKA) in older adults (≥ 75 years) suffering
The study will be conducted in the French Health insurance database (SNIIRAM). Data of octo+
patients newly treated with an oral anticoagulant (VKA or DOAC) for non valvular atrial
fibrillation (nv AF) will be collected from the first exposure of the patient to the drug of
interest during the inclusion period to the end of the follow-up period (at least one year of
follow-up for each patient)."